Genentech, Array combine Chk1 programs to improve chances of success
With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an economic incentive to favor one molecule over the other.
The long-time partners announced a new deal this month to develop a preclinical Chk1 inhibitor from Array and a Phase I compound from Genentech. Although Genentech is responsible for development and commercialization, Array is eligible for the same payouts regardless of which program is advanced.
The terms included $28 million up front to Array, up to $685 million in clinical and commercial milestones, and double-digit royalties.